Short- versus long-term, gender and species differences in the intestinotrophic effects of long-acting glucagon-like peptide 2 analog
Jazyk angličtina Země Česko Médium print-electronic
Typ dokumentu časopisecké články
Odkazy
PubMed
35344672
PubMed Central
PMC9150555
DOI
10.33549/physiolres.934839
PII: 934839
Knihovny.cz E-zdroje
- MeSH
- druhová specificita MeSH
- glukagonu podobný peptid 2 * MeSH
- krysa rodu Rattus MeSH
- lidé MeSH
- peptidy farmakologie MeSH
- potkani Wistar MeSH
- psi MeSH
- syndrom krátkého střeva * farmakoterapie MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- lidé MeSH
- mužské pohlaví MeSH
- psi MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- glukagonu podobný peptid 2 * MeSH
- peptidy MeSH
Glucagon-like-peptide 2 (GLP-2) is an endogenous enteroendocrine physiological trophic peptide. Glepaglutide is a novel long-acting GLP-2 analog under development for the treatment of patients with Short Bowel Syndrome (SBS). The objective of this work was to compare the small intestinal trophic effects in both genders following short (1 week) versus long-term (26-39 weeks) GLP-2 treatment in Wistar rats and Beagle dogs. Following both short- and long-term treatment with glepaglutide, a significant dose-dependent intestinotrophic effect was seen in both genders and species. At all doses increased length and weight of the small intestine as well as macroscopic thickening and villous hypertrophy were noted in all segments of the small intestine, without any differences between genders. The findings were still present following a 6-week recovery period, indicating long-acting intestinotrophic effects of glepaglutide. These studies demonstrate that a long-acting GLP-2 analogue (glepaglutide) has a fast onset and long duration of intestinotrophic action with similar profile in both genders and species (rat and dog).
